BioSig’s PURE EP™ System to be Showcased at EPLive 2022


Westport, CT, May 25, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company advancing the electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that its flagship technology will be showcased at EPlive, a hybrid event taking place at St. David’s Medical Center in Austin , Texas, June 2-3, 2022.

EPLive is an intensive two-day educational meeting for clinical cardiac electrophysiologists, electrophysiology fellows, and general cardiologists interested in the treatment of complex cardiac arrhythmias. During the event, BioSig will exhibit and provide technology demonstrations, including features of its new PURE EP NOVA-5 software. Enhanced with NOVA-5 software, the company believes the PURE EP(TM) system offers a new standard in signal processing, providing greater customization and smarter workflows. Additionally, the company will showcase the next generation of PURE EP(TM) software modules currently in advanced stages of development.

The concept of EPLive was first created and developed by Dr. Andrea Natale, Cardiac Electrophysiologist at St. David’s Medical Center in Austin, Texas. As an internationally renowned physician and leader in the field of Cardiac Electrophysiology, Dr. Natale is passionate about education, training, and knowledge sharing when it comes to providing the best care possible to patients. patients with arrhythmia. As the first center to commercially adopt the PURE EP(TM) System, Dr. Natale and physicians at the Texas Cardiac Arrhythmia Institute (TCAI) have treated over 500 cases with the PURE EP(TM) System since its installation in November 2019 .

“We have spent approximately thirteen years working with the physicians at TCAI to bring this important innovation to market. Our collaboration with this Center of Excellence has supported our business in so many positive ways and we are thrilled to be part of this great event,” commented Kenneth L. Londoner, President and CEO of BioSig Technologies, Inc.

To register for the event, please Click here.

The PURE EP(TM) is an FDA 510(k) cleared Class II non-invasive device that aims to improve the efficiency and effectiveness of cardiac electrophysiology procedures. To date, more than 73 doctors have finished more 2,200 cases of patients with the PURE EP(TM) system.

Clinical data acquired by the PURE EP™ System in a multi-center study at centers of excellence, including the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center and the Mayo Clinic, was recently published in the Journal of Cardiovascular Electrophysiology and are available electronically for open access via the Wiley Online Library. Study results showed a 93% consensus among blinded reviewers with an overall 75% improvement in intracardiac signal quality and confidence in interpreting PURE EP™ signals compared to conventional sources.

About EP Live
EPLive is an intensive two-day educational meeting for clinical cardiac electrophysiologists, electrophysiologist trainees, and general cardiologists interested in the treatment of complex cardiac arrhythmias, a condition in which the heart beats with an irregular or abnormal rhythm. Live cases streamed from the new state-of-the-art Electrophysiology Center at St. David’s Medical Center, with expert commentary, will serve as the primary teaching tool. EPLive consists of four sections: Atrial Fibrillation (A Fib) Ablation, Ventricular Tachycardia (VT) Ablation, Devices and New Technology. The sessions consist of a combination of live and recorded cases from TCAI and some of the best centers in the world. Cases include procedures such as A Fib ablation and post-A Fib atrial arrhythmia ablation, VT ablation (endocardial and epicardial), balloon cases (cryo, Apama, and laser), CRT implants, DCI SQ and lead extraction and venoplasty. Additionally, EPLive will feature new technology developed by TCAI physicians, including lead-free electroporation and dual-chamber stimulation.

About BioSig Technologies
BioSig Technologies is a medical technology company that markets a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intracardiac signals (www.biosig.com).

The Company’s first product, PURE EPä System, is a computer-based system for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures ) in a PE laboratory.

Forward-looking statements
This press release contains “forward-looking statements”. Such statements may be preceded by the words “intends”, “may”, “will”, “plans”, “expects”, “anticipates”, “projects”, “predicts”, “estimates”. , “aim”, “believe”. ‘, ‘hope’, ‘potential’ or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the Company and cannot be predicted or quantified and, therefore, the actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future by if need be, (ii) our inability to manufacture our products and product candidates on a commercial scale by ourselves or in conjunction with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competitors; (v) the loss of one or more key executives or scientists; and (vi) difficulties obtaining regulatory approval to commercialize our products and product candidates. More detailed information about the company and the risk factors that may affect the making of forward-looking statements is set forth in the company’s filings with the Securities and Exchange Commission (SEC), including the company’s annual report on Form 10. -K and its Quarterly Report Reports on Form 10-Q. Investors and security holders are urged to read these materials free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.


        
Previous Houston Schools and Educators Respond to Uvalde Shooting
Next 12 Winners Announced for Arizona's Future Careers Art Competition